Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.
about
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersA randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancerLoss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis.Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reactionA phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.Innovative therapeutic strategies in the treatment of brain metastases.Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1.Androgen receptor regulates SRC expression through microRNA-203KLF4 functions as an activator of the androgen receptor through reciprocal feedback.Targeting angiogenesis for the treatment of prostate cancer.Cediranib: a VEGF receptor tyrosine kinase inhibitor.Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario.Update on bevacizumab and other angiogenesis inhibitors for brain cancer.Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway.Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.Updating advances on recombinant human endostatin combined with radiotherapy for non-small cell lung cancer with brain metastasis.Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer.Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
P2860
Q28082793-A40452E3-34D3-483E-A937-86DC564269E1Q33415009-2918BAE5-3874-41F2-83B9-CE2D6F3D83B4Q33977056-6B529992-23F4-424B-B243-98FEB9F75477Q35238489-9649DBBF-25DC-4DDE-89A8-1167DB282251Q35573029-719D3057-FAF5-48C0-BB69-67AD8A4CFF20Q35966757-0A7CAB46-3C65-4E31-A293-8703B55716B0Q36013452-4CC78ED5-A1DB-403B-8F38-464BC834C481Q36031619-600BFBC3-D1F2-40BF-8B6D-C1C200F93062Q36590195-B3F4F8CB-6202-4619-8CD2-5AB7D06F462AQ36864032-57F805FA-84C6-47E0-BB11-B15C14537840Q37007828-993C3CB5-9976-436C-9C4C-5A720D132400Q37295473-0F5CBE90-2FFF-4DEF-84B7-27A803426AFDQ37525801-ABB0B7F1-56FC-46F1-AF91-C4EC7580E34EQ37993137-8B1ECEBD-A469-478B-A4D3-2BC223966261Q38029363-7FD10FF1-56E1-4610-8A5A-AC563B39F23FQ38066590-D2B9DCBE-F8AA-48B8-9F68-A36B4AD59DDEQ38106370-B1B84857-01A2-4BAC-8858-B2B2F5ED6CB7Q38262816-55A4D21C-3D0C-4E25-B48C-A082D0A25D3DQ38926353-80B29AB9-B785-4E78-B7FF-F5C7160C3295Q39174448-7264B4D7-684E-4296-A9AE-4ABA95C6FB1FQ42152039-F07AC45A-55E3-4E8C-8CCD-97DD686ADDB4Q42402968-2D4BCEC2-60AD-4A0C-BCAE-2C49533CDEF6Q49887950-D3CBA908-7BA9-4211-AC5D-C847BDAF58DDQ50899921-0077964F-4A57-4C2C-A69A-EA1731404295
P2860
Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Cediranib/AZD2171 inhibits bon ...... l of advanced prostate cancer.
@ast
Cediranib/AZD2171 inhibits bon ...... l of advanced prostate cancer.
@en
Cediranib/AZD2171 inhibits bon ...... l of advanced prostate cancer.
@nl
type
label
Cediranib/AZD2171 inhibits bon ...... l of advanced prostate cancer.
@ast
Cediranib/AZD2171 inhibits bon ...... l of advanced prostate cancer.
@en
Cediranib/AZD2171 inhibits bon ...... l of advanced prostate cancer.
@nl
prefLabel
Cediranib/AZD2171 inhibits bon ...... l of advanced prostate cancer.
@ast
Cediranib/AZD2171 inhibits bon ...... l of advanced prostate cancer.
@en
Cediranib/AZD2171 inhibits bon ...... l of advanced prostate cancer.
@nl
P2093
P2860
P1433
P1476
Cediranib/AZD2171 inhibits bon ...... l of advanced prostate cancer.
@en
P2093
Jeeva Munasinghe
Juan Juan Yin
Kathleen Kelly
Luhua Zhang
R Ilona Linnoila
P2860
P304
P356
10.1158/0008-5472.CAN-10-1435
P407
P577
2010-10-19T00:00:00Z